Semaglutide 2.4 mg (Wegovy) is approved under NICE technology appraisal TA875, and tirzepatide (Mounjaro) has also received a NICE technology appraisal for weight management
Unlike stimulant-heavy diet pills or restrictive detox products, it focuses on the body's own hormonal pathways, specifically GLP-1 (glucagon-like peptide-1) activity, to encourage satiety, stabilize energy, and promote long-term metabolic health
[2] [3] Common adverse effects of Wegovy, as listed in the MHRA/EMC Summary of Product Characteristics, include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, constipation, and abdominal pain
Oliver89 No delays, the parcel arrived on schedule
Health 4 , e604e614 (2022)
1 However, this is primarily a concern for medications with a narrow therapeutic index (where small changes in blood levels can cause problems) or those that require rapid absorption for effectiveness